Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasm Metastasis 38Leukemia, Myeloid, Acute 35Multiple Myeloma 29Lymphoma 23Breast Neoplasms 19Colorectal Neoplasms 18Prostatic Neoplasms 17Pancreatic Neoplasms 17Myelodysplastic Syndromes 15Lymphoma, Large B-Cell, Diffuse 15Leukemia, Lymphocytic, Chronic, B-Cell 15Burkitt Lymphoma 15Lung Neoplasms 14Triple Negative Breast Neoplasms 13Melanoma 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Ovarian Neoplasms 12Carcinoma, Non-Small-Cell Lung 12Sarcoma 10Neuroblastoma 9Neoplasms 9Lymphoma, T-Cell 9Glioma 9Carcinoma, Renal Cell 9Squamous Cell Carcinoma of Head and Neck 8Fallopian Tube Neoplasms 8Endometrial Neoplasms 8Myeloproliferative Disorders 7Lymphoma, Non-Hodgkin 7Lymphoma, Mantle-Cell 7

Interventions

Specimen Handling 1Biopsy 13-aminopyridine-2-carboxaldehyde thiosemicarbazone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Serous Adenocarcinoma × Biopsy × 90 days × Clear all
NCT04494113 2026-05-13

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

National Cancer Institute (NCI)

Phase EARLY_PHASE1 Active not recruiting
12 enrolled
Gynecologic

Endometrial Serous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡